Clinical Trials
48 trialsNCT02979977 2026-02-04
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
Phase 2 Completed
NCT05517330 2025-07-31
neoCHANCE-1
West China Hospital
Phase 2 Completed
NCT05516589 2025-05-22
neoCHANCE-2
West China Hospital
Phase 2 Completed
NCT05298176 2025-03-28
COMBINATION
Amsterdam UMC, location VUmc
Phase 2 Completed
NCT02597946 2025-02-19
Afatinib in NSCLC With HER2 Mutation
Boehringer Ingelheim
Phase 2 Completed
NCT03083678 2025-02-13
Afatinib in Locally Advanced and Metastatic Chordoma
Leiden University Medical Center
Phase 2 Completed
NCT04839471 2024-07-08
BEAR
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT04410653 2024-04-05
Afatinib in Advanced NRG1-Rearranged Malignancies
German Cancer Research Center
Phase 2 Completed
NCT01542437 2024-02-06
NSCLC
Instituto Nacional de Cancerologia de Mexico
Phase 2 Completed
NCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02183883 2023-11-29
DARWIN1
University College, London
Phase 2 Completed
NCT01522768 2023-11-01
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03727724 2023-10-18
AFACET
The Netherlands Cancer Institute
Phase 2 Completed
NCT02506517 2023-08-01
A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene
University Health Network, Toronto
Phase 2 Completed
NCT02501603 2023-01-27
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Yonsei University
Phase 2 Completed
NCT04201756 2022-12-23
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Completed
NCT02716311 2022-08-11
ACE-Lung
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT03695510 2022-04-21
ALPHA
National Taiwan University Hospital
Phase 2 Completed
NCT01156545 2022-04-06
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
National Cancer Center, Korea
Phase 2 Completed
NCT01415674 2022-02-02
PREDICTOR
UNICANCER
Phase 2 Completed
NCT02629523 2021-08-03
LiquidLung-A
Chonnam National University Hospital
Phase 2 Completed
NCT02747953 2021-03-19
Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib
Samsung Medical Center
Phase 2 Completed
NCT03157089 2021-02-23
LUX-Lung-IO
Boehringer Ingelheim
Phase 2 Completed
NCT02780687 2020-11-18
LUX-Bladder 1
Boehringer Ingelheim
Phase 2 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT01271725 2019-06-17
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Boehringer Ingelheim
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01415011 2019-01-15
TIMELY
University College, London
Phase 2 Completed
NCT01538381 2018-07-09
Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01919879 2018-05-08
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
UNICANCER
Phase 2 Completed
NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00727506 2017-08-15
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Boehringer Ingelheim
Phase 2 Completed
NCT00525148 2016-09-16
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Boehringer Ingelheim
Phase 2 Completed
NCT00514943 2016-07-26
BIBW 2992 (Afatinib) in Head & Neck Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT02625168 2015-12-09
Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
The University of Hong Kong
Phase 2 Completed
NCT01441596 2015-09-07
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
Phase 2 Completed
NCT00706628 2015-01-15
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00711594 2015-01-15
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
Boehringer Ingelheim
Phase 2 Completed
NCT00796549 2014-07-22
BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
Boehringer Ingelheim
Phase 2 Completed
NCT01152437 2014-06-26
A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00431067 2014-06-09
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Boehringer Ingelheim
Phase 2 Completed
NCT00730925 2014-03-26
Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
Boehringer Ingelheim
Phase 2 Completed
NCT01594177 2014-03-13
DAFNE
GBG Forschungs GmbH
Phase 2 Completed
NCT00425854 2013-12-31
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00826267 2013-12-31
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Boehringer Ingelheim
Phase 2 Completed
NCT01003899 2013-12-31
A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]
Boehringer Ingelheim
Phase 2 Completed
NCT00708214 2013-12-30
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00875433 2013-12-30
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
Boehringer Ingelheim
Phase 2 Completed